Rhenman & Partners Asset Management’s Denali Therapeutics DNLI Stock Holding History

Rhenman & Partners Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.6M	Sell	179,000 -20,000	-10%	-$411K	0.43%	75
2026 Q1	$3.82M	Buy	199,000 +99,000	+99%	+$1.97M	0.47%	64
2025 Q4	$1.65M	Hold	100,000	–	–	0.15%	91
2025 Q3	$1.45M	Hold	100,000	–	–	0.16%	87
2025 Q2	$1.4M	Hold	100,000	–	–	0.18%	80
2025 Q1	$1.36M	Buy	+100,000	New	+$1.92M	0.16%	75

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rhenman & Partners Asset Management's DNLI Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Denali Therapeutics (DNLI) stake by 10% in Q2 2026, selling an estimated $411K and leaving 179,000 shares worth $4.6M. The position accounts for 0.43% of the portfolio, ranked #75.

Rhenman & Partners Asset Management first reported a position in DNLI in Q1 2025 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Rhenman & Partners Asset Management held 179,000 shares of Denali Therapeutics worth $4.6M as of Q2 2026.
Rhenman & Partners Asset Management sold 20,000 Denali Therapeutics shares in Q2 2026, an estimated $411K.
Denali Therapeutics made up 0.43% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #75 holding.
Rhenman & Partners Asset Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 6 quarters since.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.